Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
KymaThera
Biotech developing an oral pan-mutant selective PI3Kα inhibitor for breast cancer and vascular malformations.
What they do
KymaThera closed an $80M Series B in October 2026 led by Alta Partners with Venrock, Foresite Capital and J. Wood Capital, bringing total funding above $100M. Its lead drug K-1728 is designed to block mutant PI3Kα while sparing the normal enzyme, with Phase 1 dosing in HR+/HER2- breast cancer and PI3Kα-driven vascular malformations expected in late 2026.
The record
- Vertical
- Biotech & Therapeutics
- Sub-segment
- Precision oncology
- Product type
- Therapeutic
- Stage
- Series B
- Headquarters
- San Diego, United States
- Region
- North America
- Founded
- Not disclosed
- Total funding
- $100M raised
Notable investors: Alta Partners, Venrock, Foresite Capital, J. Wood Capital.
Also in Biotech & Therapeutics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
Liquid biopsy monitoring is turning precision oncology into a continuous process, not a one time test
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA